http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009281135-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_20ccbdcb3f3122351819d53bf69cdc29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e661e410bb5ea5aa9d2ba29f01431db http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ae587697d9975b193347b0df6da47ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e69ec2b8a19c1700b3623f843dc68965 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-22 |
| filingDate | 2007-09-07^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_023a3bd7a19e51ff69cc92ec801b203c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b49b9d35b9a53a3889fe9c324a852fca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a81906d94202fd1d12b977f8fb9586a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6953b50c6fcc9471e422ff14d5d6ffab |
| publicationDate | 2009-11-12^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2009281135-A1 |
| titleOfInvention | 3-azabicyclo [4. 1. 0] heptane derivatives for the treatment of depression |
| abstract | The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof: n n n n n n n n n n whereinn G is selected from the group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, and a 8- to 11-membered heteroaryl bicyclic group; wherein G may be substituted by (R 2 ) p , which can be the same or different; R 1 is hydrogen or C 1-4 alkyl; R 2 is halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl or SF 5 ; or corresponds to R 8 ; R 5 is hydrogen or C 1-4 alkyl; R 6 is hydrogen or C 1-4 alkyl; R 7 is selected from the group consisting of: hydrogen, fluorine, and C 1-4 alkyl; or corresponds to X, X 1 , X 2 or X 3 ; wherein X corresponds to: nn n n n n n n n n n X 1 corresponds to: n n n n n n n n n n n n X 2 corresponds to: n n n n n n n n n n n n X 3 corresponds to: n n n n n n n n n n n n R 3 is hydrogen or C 1-4 alkyl; or corresponds to X or X 1 ; n R 4 is hydrogen or C 1-4 alkyl; or corresponds to X or X 1 ; n R 8 is a 5-6 membered heterocycle group, which may be substituted by one or two substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy and C 1-4 alkanoyl; n R 9 is C 1-4 alkyl; n R 10 is hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl or C 3-6 cycloalkylC 1-3 alkyl; n R 11 is haloC 1-2 alkyl; n p is an integer from 0 to 5; and n n is 1 or 2;n nand processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors. |
| priorityDate | 2006-09-11^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 954 of 954.